USA flag logo/image

An Official Website of the United States Government

In vivo profiling for oral candidiasis drug target discovery

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
76134
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
DE017033
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
GUILD ASSOCIATES, INC.
5750 SHIER-RINGS RD DUBLIN, OH 43016-1234
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2009
Title: In vivo profiling for oral candidiasis drug target discovery
Agency: HHS
Contract: 2R44DE017033-02A1
Award Amount: $724,482.00
 

Abstract:

DESCRIPTION (provided by applicant): Candida albicans is the most frequently isolated fungal pathogen of humans and represents an important public health problem. However, antifungal treatments are hampered by emerging resistance, toxicity concerns, lack o f fungicidal activity, and narrow spectrum of action. Thus, there is a critical need for new antifungal drug targets, and new antifungal drug strategies. An important step in the identification of new targets for antifungal drug discovery is the use of in vivo genome profiling using appropriate diseased samples to identify fungal-specific genes which are required for infection. The Phase I application successfully utilized emerging technologies to identify C. albicans genes induced during murine oral candid iasis. Specifically, we identified a subset of: (i) in vivo expressed genes; (ii) infection and colonization-associated genes, and (iii) novel and fungal-specific genes that will likely play a role in the transition from comced targets identified during th e Phase I research are required for oral infection. Specific C. albicans knockout strains will be generated and assessed for their ability to cause disease during oral candidiasis. Specific Aim 2 will demonstrate that oligonucleotides can function as antif ungal agents against Candida species in vitro. Oligonucleotides will be designed against pre-existing antifungal drug targets and against infection- required targets identified in Specific Aim 1. The oligonucleotides will be preferentially designed against domains within the gene open reading frame that are conserved amongst pathogenic fungi. The antifungal capability of the oligonucleotides will be assessed specifically at the mRNA level, and analyzed for the corresponding alterations in growth, viability, or specific phenotype trait. Specific Aim 3 will demonstrate that the oligonucleotides can be used alone, and in combination with known antifungal agents, to treat murine oral candidiasis. The rese Mucosal candidiasis is the mostcommon type of Candida inf ection and occurs frequently in immunocompromised patients, and patients with an altered bacterial flora. Despite the large number of at risk patients, antifungal treatment is hampered by toxic side effects and emerging antifungal resistant Candida strains and species.

Principal Investigator:

David A. Schofield
8435730095
DSCHOFIELD@GUILDASSOCIATES.COM

Business Contact:

Robert Freeburn
Small Business Information at Submission:

GUILD ASSOCIATES, INC.
GUILD ASSOCIATES, INC. 5750 SHIER-RINGS RD DUBLIN, OH 43016

EIN/Tax ID: 310998683
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No